Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: GregorioAllegri who wrote (2913)	11/2/2013 12:01:24 AM
From: Biomaven	Read Replies (2) \| Respond to of 4474

But nilotinib clearly has the same effects - read the Kim paper. That paper states that in one trial: 35.7% receiving nilotinib as second-line therapy developed PAOD (peripheral artery occlusive disease). Granted the VEGFR2 block might add to the issue, but there has to be something that both pona and nilotinib hits that is doing this. I do agree that pona's future lies only in T315i/ true third line in CML, and perhaps GIST and medullary thyroid. Peter

To: GregorioAllegri who wrote (2913)	11/2/2013 8:23:18 AM
From: iandy	Read Replies (1) \| Respond to of 4474

>This should be a great trading (gambling) stock for a while. A mine field for both longs and shorts as new will move this big time in both directions.< I liked the gamble better when Iclusig was still on the table. It appears that if the drug comes back it will have limited value. Ariad is almost a one trick pony now and we know AP26113 is having it's own problems in the clinic. On top of that, I don't understand how anyone can trust this outfit after they seemingly misled everyone on the safety issues with Iclusig. The bottom line is trading a stock like this is now is too much of a gamble for even a riverboat guy like me.